ISRCTN08234512CompletedPhase 1
A Phase I trial evaluating mucosal administration of a candidate TB vaccine, MVA85A, as a way to induce potent local cellular immune responses and avoid anti-vector immunity
niversity of Oxford (UK)0 sites36 target enrollmentStarted: November 8, 2013Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 36
Study Overview
Brief Summary
2019 results in: https://www.ncbi.nlm.nih.gov/pubmed/31039172 (added 03/07/2019)
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Healthy adult aged 18-55 years
- •2. Resident in or near Oxford for the duration of the trial period
- •3. No relevant findings in medical history or on physical examination
- •4. Confirmation of prior vaccination with BCG not less than 6 months prior to projected trial vaccination date (by visible BCG scar on examination or written documentation)
- •5. Allow the investigators to discuss the individual?s medical history with their GP
- •6. Use effective contraception for the duration of the trial period (females only)
- •7. Refrain from blood donation during the trial
- •8. Give written informed consent
- •9. Allow the Investigator to register subject details with a confidential database to prevent concurrent entry into clinical trials
- •10. Able and willing (in the investigator?s opinion) to comply with all the trial requirements
Exclusion Criteria
- •1. Any respiratory disease, including asthma
- •2. Current smoker
- •3. Clinically significant abnormality on screening chest X-ray
- •4. Clinically significant abnormality of pulmonary function tests
- •5. Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy
- •6. Current use of any medication taken through the nasal or inhaled route including cocaine or other recreational drugs
- •7. Laboratory evidence at screening of latent M. tuberculosis infection as indicated by a positive ELISPOT response to ESAT6 or CFP10 antigens
- •8. Clinical, radiological, or laboratory evidence of current active TB disease
- •9. Previous vaccination with candidate vaccine MVA85A or candidate vaccine FP85A or any other recombinant MVA vaccine
- •10. Clinically significant history of skin disorder, allergy, immunodeficiency (including HIV), cancer (except BCC or CIS), cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse
- •11. History of serious psychiatric condition
- •12. Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents
- •13. History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine, sedative drugs, or any local or general anaesthetic agents
- •14. Any abnormality of screening blood or urine tests that is deemed to be clinically significant or that may compromise the safety of the subject in the trial
- •15. Positive HBsAg, HCV or HIV antibodies
- •16. Female currently lactating, confirmed pregnancy or intention to become pregnant during trial period
- •17. Use of an investigational medicinal product or non-registered drug, live vaccine, or medical device other than the trial vaccine for 30 days prior to dosing with the trial vaccine, or planned use during the trial period
- •18. Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial vaccination date
- •19. Any other significant disease, disorder or finding, which, in the opinion of the investigator, may either put the subject at risk or may influence the result of the trial or may affect the subject?s ability to participate in the trial
Investigators
Similar Trials
Completed
Phase 2
A study of the drugs AZD2014 and rituximab in relapsed or refractory diffuse large B-cell lymphomaTopic: CancerSubtopic: LymphomaDisease: Lymphoma (other)CancerISRCTN10760016niversity of Birmingham36
Completed
Not Applicable
A study to investigate the effect of a sensitivity toothpaste in providing relief from tooth sensitivityTooth sensitivityOral HealthISRCTN16831120GlaxoSmithKline Consumer Healthcare240
Completed
Phase 3
A phase III, randomized, open-label, 500-subject clinical trial of minimally invasive surgery plus rtPA in the treatment of intracerebral haemorrhageISRCTN81927110Johns Hopkins University500
Completed
Phase 3
Thyroid AntiBodies and LEvoThyroxine study (TABLET)Spontaneous abortionISRCTN15948785niversity of Birmingham (UK)952
Completed
Phase 3
A phase III, randomised, controlled trial for the treatment of HIV-associated cryptococcal meningitis: oral fluconazole plus flucytosine or one week amphotericin B-based therapy vs two weeks amphotericin B-based therapyISRCTN45035509St George's University of London (UK)680